Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3609882rdf:typepubmed:Citationlld:pubmed
pubmed-article:3609882lifeskim:mentionsumls-concept:C0014544lld:lifeskim
pubmed-article:3609882lifeskim:mentionsumls-concept:C0016295lld:lifeskim
pubmed-article:3609882lifeskim:mentionsumls-concept:C1521725lld:lifeskim
pubmed-article:3609882lifeskim:mentionsumls-concept:C1524063lld:lifeskim
pubmed-article:3609882pubmed:issue4lld:pubmed
pubmed-article:3609882pubmed:dateCreated1987-9-9lld:pubmed
pubmed-article:3609882pubmed:abstractTextUsing the same technique as Declerk's and Wauquier's, we added flunarizine to standard therapy in 14 patients, 7 of whom were treated with the sequence flunarizine-placebo and 7 with the sequence placebo-flunarizine. Treatment averaged between 75 and 85 days, with medication administered in a single dose (orally, in drops), 5-10 mg/day. The patients comprised 7 males and 7 females, from 13 to 17 years with the following diagnoses: epileptic encephalopathy 6 cases, grand mal, myoclonic epilepsy, multifocal epilepsy, epilepsy with polymorphic seizures, 2 cases each. Age, sex and disease were distributed equally in both sequences. During treatment with flunarizine we observed the following: 7 cases--no effect on number or severity of seizures; 2 cases--moderate results; 5 cases--good results.lld:pubmed
pubmed-article:3609882pubmed:languageenglld:pubmed
pubmed-article:3609882pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3609882pubmed:citationSubsetIMlld:pubmed
pubmed-article:3609882pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3609882pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3609882pubmed:statusMEDLINElld:pubmed
pubmed-article:3609882pubmed:issn0393-5264lld:pubmed
pubmed-article:3609882pubmed:authorpubmed-author:CavazzutiG...lld:pubmed
pubmed-article:3609882pubmed:authorpubmed-author:GalliVVlld:pubmed
pubmed-article:3609882pubmed:authorpubmed-author:BenattiAAlld:pubmed
pubmed-article:3609882pubmed:issnTypePrintlld:pubmed
pubmed-article:3609882pubmed:volume1lld:pubmed
pubmed-article:3609882pubmed:ownerNLMlld:pubmed
pubmed-article:3609882pubmed:authorsCompleteYlld:pubmed
pubmed-article:3609882pubmed:pagination551-4lld:pubmed
pubmed-article:3609882pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3609882pubmed:meshHeadingpubmed-meshheading:3609882-...lld:pubmed
pubmed-article:3609882pubmed:meshHeadingpubmed-meshheading:3609882-...lld:pubmed
pubmed-article:3609882pubmed:meshHeadingpubmed-meshheading:3609882-...lld:pubmed
pubmed-article:3609882pubmed:meshHeadingpubmed-meshheading:3609882-...lld:pubmed
pubmed-article:3609882pubmed:meshHeadingpubmed-meshheading:3609882-...lld:pubmed
pubmed-article:3609882pubmed:meshHeadingpubmed-meshheading:3609882-...lld:pubmed
pubmed-article:3609882pubmed:meshHeadingpubmed-meshheading:3609882-...lld:pubmed
pubmed-article:3609882pubmed:meshHeadingpubmed-meshheading:3609882-...lld:pubmed
pubmed-article:3609882pubmed:meshHeadingpubmed-meshheading:3609882-...lld:pubmed
pubmed-article:3609882pubmed:meshHeadingpubmed-meshheading:3609882-...lld:pubmed
pubmed-article:3609882pubmed:meshHeadingpubmed-meshheading:3609882-...lld:pubmed
pubmed-article:3609882pubmed:articleTitleThe use of flunarizine in pediatric epilepsy.lld:pubmed
pubmed-article:3609882pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3609882pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:3609882pubmed:publicationTypeControlled Clinical Triallld:pubmed